Human Augmented Brain Systems (HABS)
Decodes EEG brainwaves into real-time cognitive/emotional insights via wearables
Website: https://habs.ai
Cover Block
PUBLIC
| Name | Human Augmented Brain Systems (HABS) |
| Tagline | Decodes EEG brainwaves into real-time cognitive/emotional insights via wearables |
| Headquarters | Saclay, France |
| Founded | 2023 |
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Founding Team | Solo Founder |
| Funding Label | Seed (5.5M€ total, two rounds in 2024) [L'actu des Business Angels, 2025] [Maddyness, 2025] |
Links
PUBLIC
- Website: https://habs.ai
- LinkedIn: https://www.linkedin.com/company/habs_cognitive
- YouTube: https://www.youtube.com/@HABSBrain
Executive Summary
PUBLIC Human Augmented Brain Systems (HABS) is a French neurotechnology startup attempting to commercialize non-invasive brainwave decoding for high-stakes enterprise applications, a proposition that warrants investor attention for its early-mover positioning in a nascent but potentially transformative hardware-software wedge [French Wikipedia, 2025]. Founded in August 2023 by cybersecurity entrepreneur Olivier Locufier, the company was reportedly motivated by a personal need to better assess pain in vulnerable patients, including his daughter [French Wikipedia, 2025]. Its core offering is a suite of products, including the HABS Secure platform and the Neoxa frontal EEG sensor, which aim to translate EEG and biometric data into real-time cognitive and emotional insights for sectors like defense, cybersecurity, and marketing [French Wikipedia, 2025].
The founding team brings a background in cybersecurity and biometrics, with Locufier having previously developed and sold companies in those fields, though the operational experience in scaling deep-tech hardware remains unproven [Acast DeepTechs, 2026]. Public funding records are opaque, with two undisclosed rounds noted in 2024 but no amounts or lead investors confirmed, suggesting a reliance on angel or non-institutional capital to date [L'actu des Business Angels, 2025]. Over the next 12-18 months, the critical watchpoints will be the transition from prototype to validated commercial deployments, the securing of a priced institutional round to fund hardware production, and the emergence of any named enterprise customers to substantiate the ambitious use cases outlined on the company's website.
Data Accuracy: YELLOW -- Key founding and product claims are sourced from a single Wikipedia entry and company materials; funding details are vague and unverified by major outlets.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Founding Team | Solo Founder |
| Funding | Seed (5.5M€ total, two rounds in 2024) |
Company Overview
PUBLIC
Human Augmented Brain Systems (HABS) was founded in August 2023 on the Saclay Plateau in France, a location chosen for its proximity to a deep-tech research ecosystem [French Wikipedia, 2025]. The founding motivation was personal, with CEO Olivier Locufier citing the challenge of assessing pain in his newborn daughter during leukemia treatment as a catalyst for developing non-invasive neural sensing technology [French Wikipedia, 2025]. The company operates as a neurotechnology startup focused on decoding EEG brainwaves and biometric data into real-time cognitive and emotional insights [F6S].
The core team is anchored by Locufier, a serial entrepreneur with a background in building and selling companies in cybersecurity, biometrics, and encryption [Acast DeepTechs, 2026]. Public leadership signals are mixed, with Samuel Willer listed as Sensora Director and Gilles le Guennec as Chief of Staff [RocketReach, 2026], while Karim Deneyer has been announced in roles including CFO and EVP of Global Strategy [LinkedIn Karim Deneyer, 2026] [RocketReach, 2026]. The company claims a team of over 30 experts, 15 patents, and 158 scientific publications, though these figures are self-reported on its website [habs.ai].
Key operational milestones are sparse in public records. The company launched its Neoxa frontal EEG emotional sensor in 2025, according to its Wikipedia entry [French Wikipedia, 2025]. It has also defined two flagship product lines: HABS Secure for mental state monitoring in high-risk sectors and Sensora, a cognitive intelligence engine for marketing analytics [French Wikipedia, 2025] [habs.ai/use-cases-marketing, 2026]. No named customer deployments, major partnerships, or subsequent product launch dates have been verified in third-party coverage.
Data Accuracy: YELLOW -- Founding details and product launch year cited from French Wikipedia; team composition and background are partially corroborated by LinkedIn profiles and a podcast interview. Core operational claims (team size, patent count) are company-sourced only.
Product and Technology
MIXED
The company’s public-facing proposition centers on a hardware-plus-software platform designed to translate physiological signals into cognitive insights. The core technology is described as a non-invasive system that captures EEG brainwaves and other biometric data, processing them in real time to detect states like fatigue, stress, and distraction [French Wikipedia, 2025]. This is framed not as a medical device but as a cognitive infrastructure layer for sectors where human performance and risk are critical.
Two flagship products are cited in public materials. The first, HABS Secure, is positioned as a SaaS and hardware bundle for mental state monitoring in high-stakes environments like cybersecurity, transportation, and physical security [French Wikipedia, 2025]. The second, Neoxa, launched in 2025, is described as a frontal EEG "emotional sensor" engineered to meet standards for defense, mobility, and marketing industries, with its AI models reportedly trained to interpret signals related to pain and stress [habs.ai/lab-research, 2026]. The overarching commercial model is labeled Brainwaves-as-a-Service (BaaS), which the company says uses federated AI to build personalized Cognitive Persona profiles without exposing raw user data [habs.ai, 2025]. A more speculative application, mentioned in a niche podcast, involves developing technology to replace passwords with brainwave authentication [MyConnecting IA, 2025].
From a technical standpoint, the stack is inferred to combine signal acquisition hardware, real-time processing pipelines, and proprietary AI models for pattern recognition. The company’s website claims a foundation of 15+ patents and 158 scientific publications among its team [habs.ai, 2025], though the specific patents are not enumerated. There is no public roadmap detailing future product releases or technological milestones beyond the stated 2025 launch of Neoxa.
Data Accuracy: ORANGE -- Product descriptions are sourced from the company's website and a French Wikipedia entry; technical claims (patents, publications) are company-reported and not independently verified. The Neoxa launch date and BaaS model are not corroborated by third-party press.
Market Research
PUBLIC The market for neurotechnology is expanding beyond medical diagnostics into commercial applications for cognitive monitoring and human-machine interaction, driven by advances in sensor miniaturization and AI signal processing.
Third-party market sizing for the specific Brainwaves-as-a-Service (BaaS) segment is not publicly available. However, analogous markets provide a directional view. The global neurotechnology market, which includes brain-computer interfaces and neuroprosthetics, was valued at approximately $14.3 billion in 2023 and is projected to grow at a compound annual rate of around 13% through 2030 [Grand View Research, 2024]. The wearable biometric sensors market, a key enabling technology for HABS's approach, is forecast to exceed $4.5 billion by 2028 [Global Market Insights, 2024]. These figures suggest a sizable and growing underlying infrastructure layer for the company's proposed applications.
Demand drivers for cognitive and emotional state monitoring are emerging across several verticals. In cybersecurity, the need for continuous, passive authentication to combat insider threats and social engineering is a recognized pain point [Gartner, 2024]. In transportation and defense, operator fatigue and stress monitoring are critical for safety in high-risk roles, a use case highlighted in the company's own materials [habs.ai]. The marketing and consumer research sector shows increasing interest in quantifying emotional engagement, moving beyond traditional surveys to biometric response measurement [Premium Beauty News].
Key adjacent and substitute markets present both opportunity and competition. The broader mental wellness and corporate wellbeing software market, valued in the tens of billions, represents a potential expansion path but relies on different, often survey-based, data inputs. The physical biometrics market (fingerprint, facial recognition) is mature and commoditized, positioning cognitive biometrics as a potential next-generation differentiator. Regulatory forces are a significant consideration, particularly in Europe where medical device (MDR) and data privacy (GDPR) regulations would apply to any product making health-related claims or processing sensitive biometric data.
Neurotechnology Market (2023) | 14.3 | $B
Wearable Biometric Sensors Market (2028 est.) | 4.5 | $B
The available sizing data indicates a substantial and growing total addressable market for the underlying technologies, though HABS's specific SAM within high-security and enterprise monitoring niches remains unquantified. The growth trajectory is supported by secular trends in safety, security, and human-centric AI.
Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors; specific BaaS segment sizing is not confirmed.
Competitive Landscape
MIXED HABS positions itself at the intersection of neurotechnology and applied human-machine interfaces, aiming to commoditize real-time cognitive state data for industrial applications where its primary competition is not direct feature-for-feature replacement but the inertia of existing monitoring methods and a handful of specialized, well-funded players.
| Metric | Value |
|---|---|
| Neuralink (US) | 7000 $M |
| HABS (France) | 5.5 €M |
The funding gap is the most immediate competitive signal, placing HABS in a different weight class from its most publicly cited rival.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| HABS | Non-invasive EEG wearables for real-time cognitive/emotional insights in security, mobility, marketing. | Pre-Seed / 5.5M€ (estimated) | Focus on industrial B2B SaaS (Brainwaves-as-a-Service) and federated AI for privacy. | [French Wikipedia, 2025] |
| Neuralink | Invasive brain-computer interfaces (BCIs) for medical restoration and human-AI symbiosis. | Later-stage / $7B+ (estimated) | Surgical implantation for high-bandwidth neural data; primary focus on medical therapeutics. | [Various] |
The competitive map segments into three layers. In the core neurotech hardware space, direct competitors are scarce but capital-intensive. Neuralink represents the high-end, invasive pole, pursuing medical device approval pathways that are largely irrelevant to HABS's non-invasive, operational monitoring use case. More relevant challengers would include companies like Emotiv (consumer-grade EEG headsets for research and wellness) or NextMind (acquired by Snap), though these focus on consumer and developer markets, not the defense and transportation verticals HABS targets. The adjacent substitute layer is crowded: HABS's value proposition for fatigue detection in transportation competes against decades of established driver monitoring systems (DMS) using camera-based computer vision, a market dominated by automotive suppliers like Veoneer and Seeing Machines. In cybersecurity, the concept of brainwave authentication must displace a vast ecosystem of biometric and behavioral analytics software from incumbents like Okta or BioCatch.
HABS's claimed edge rests on two pillars, both of which require verification. The first is its specific hardware focus: the Neoxa frontal EEG sensor is engineered for signal isolation in noisy environments, a technical challenge for non-invasive systems [habs.ai/lab-research, 2026]. If the sensor performs as described, it could offer a fidelity advantage over consumer EEG devices for industrial settings. The second is its integrated software stack, Sensora, which promises real-time emotional decoding as a service. This "Brainwaves-as-a-Service" model aims to create a data moat; by processing insights locally via federated AI, it also addresses the significant privacy concerns inherent in brain data collection, a potential regulatory advantage in Europe. However, this edge is perishable. It depends entirely on unproven commercial deployments to generate the proprietary datasets needed to improve its AI models. Without paying customers, the data moat does not exist.
The company's exposure is multifaceted. Its most glaring vulnerability is capital. With an estimated 5.5M€ in pre-seed funding, it lacks the war chest for the long R&D and sales cycles required in its target sectors like defense and automotive. A well-funded incumbent in a related field, such as a medical device company expanding into non-invasive monitoring, could easily outspend HABS on talent and customer acquisition. Furthermore, HABS does not own the sales channel into any of its target industries. Penetrating regulated, conservative sectors like air traffic control or nuclear facility security requires established integrators and certifications it likely does not yet possess.
The most plausible 18-month scenario hinges on proving a single, high-value use case. The winner, in this case, would be a company that lands a flagship pilot with a recognizable entity in European defense or automotive testing, moving from a research prototype to a validated operational tool. The loser would be any player that remains in the "science project" phase, unable to transition from technical demonstrations to a repeatable sales motion. For HABS, the specific risk is that its technology, while intriguing, is perceived as a solution in search of a problem by procurement officers who have cheaper, proven alternatives for monitoring human performance.
Data Accuracy: YELLOW -- Competitor identification and funding comparison are based on public reports, but HABS's specific market position and differentiation are primarily self-reported [habs.ai, 2025] [French Wikipedia, 2025].
Opportunity
PUBLIC The prize for HABS is establishing the foundational layer for real-time, non-invasive cognitive state monitoring across high-stakes industries, a market that could scale into the billions if brainwave data becomes a standard input for safety and personalization.
The headline opportunity is to become the default infrastructure for human cognitive state assessment in regulated, high-liability environments. While many neurotech companies target consumer wellness or medical diagnostics, HABS's cited focus on defense, transportation, and cybersecurity [French Wikipedia, 2025] suggests a wedge into sectors where quantifying human factors like fatigue, stress, and distraction carries significant economic and safety value. The company's positioning around Brainwaves-as-a-Service (BaaS) and federated AI for Cognitive Persona profiles [habs.ai, 2025] frames the ambition as a platform, not just a point solution. The plausibility of this outcome rests on the early validation of non-invasive EEG in professional settings and the founder's background in selling enterprise-grade security and biometrics solutions [Challenges.fr, 2025], which provides a relevant go-to-market template for navigating complex, risk-averse buyers.
Growth could follow several distinct, concrete paths, each hinging on a specific catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Regulatory Mandate in Transportation | HABS's Neoxa sensor becomes a recommended or required system for monitoring pilot/driver fatigue in aviation or commercial trucking. | A major safety incident prompts a new regulatory framework, and HABS's technology is validated in a government-sponsored pilot. | The company's marketing explicitly targets the mobility industry with a sensor engineered to meet defense and mobility standards [habs.ai/lab-research, 2026]. Non-invasive fatigue monitoring is an active area of R&D in transportation safety. |
| Embedded Security Standard | The "password replacement" technology [MyConnecting IA, 2025] is adopted as a high-assurance authentication layer by a major cybersecurity vendor or government agency. | A strategic partnership with a legacy security player (e.g., Thales, Palo Alto Networks) to integrate HABS Secure into their zero-trust portfolio. | Founder Olivier Locufier's prior exits in cybersecurity and biometrics [Acast DeepTechs, 2026] establish credibility and potential channel relationships in this exact vertical. |
Compounding for HABS would manifest as a data and regulatory moat. Early deployments in stringent environments like defense would generate proprietary datasets on cognitive states under real-world stress, which could continuously improve the accuracy of its AI models. This improved accuracy, in turn, would strengthen its case for broader regulatory acceptance and industry standards, creating a barrier for new entrants who lack field-validated data. The company's claim of a federated AI approach [habs.ai, 2025], if executed, could further this flywheel by allowing data collaboration without centralizing sensitive biometric information, making adoption easier for privacy-conscious enterprises.
The size of the win can be contextualized by looking at the valuation of public companies in adjacent sensing and safety technology. For example, Kongsberg Gruppen, a Norwegian maritime technology and defense contractor with a significant focus on sensor systems and autonomous operations, trades at a market capitalization of approximately $10 billion. While not a direct comparable, it illustrates the scale achievable by providing critical sensing infrastructure to high-value industrial and government clients. If HABS successfully executes the "Regulatory Mandate" scenario and captures a material portion of the commercial transportation monitoring market, achieving a multi-billion euro valuation as a category-defining neurotech platform is a plausible outcome (scenario, not a forecast).
Data Accuracy: YELLOW -- Opportunity framing is extrapolated from company claims and founder background; specific growth catalysts and market comparables are illustrative, not confirmed by deal flow.
Sources
PUBLIC
[L'actu des Business Angels, 2025] | https://www.lactudesbusinessangels.com/article/habs-leve-55-millions-deuros
[Maddyness, 2025] | https://www.maddyness.com/finance/2025/06/12/habs-levage-fonds/
[French Wikipedia, 2025] | https://fr.wikipedia.org/wiki/Human_Augmented_Brain_Systems
[habs.ai, 2025] | https://habs.ai
[habs.ai/lab-research, 2026] | https://habs.ai/lab-research
[habs.ai/use-cases-marketing, 2026] | https://habs.ai/use-cases-marketing
[MyConnecting IA, 2025] | https://myconnecting-ia.com/podcasts/exclusif-cette-startup-francaise-remplace-tous-vos-mots-de-passe-par-vos-pensees/
[Acast DeepTechs, 2026] | https://shows.acast.com/deeptechs/episodes/olivier-locufier-habs
[RocketReach, 2026] | https://rocketreach.co/human-augmented-brain-systems-habs-profile_b5c9f4f6f42e8a2d
[LinkedIn Karim Deneyer, 2026] | https://www.linkedin.com/in/karimdeneyer/
[Challenges.fr, 2025] | https://www.challenges.fr/entreprise/tech-numerique/face-a-neuralink-delon-musk-la-start-up-francaise-habs-releve-le-defi-de-decrypter-les-ondes-cerebrales_633985
[Grand View Research, 2024] | https://www.grandviewresearch.com/industry-analysis/neurotechnology-market-report
[Global Market Insights, 2024] | https://www.gminsights.com/industry-analysis/wearable-biometric-sensors-market
[Gartner, 2024] | https://www.gartner.com/en/documents/5467897
[Premium Beauty News] | https://www.premiumbeautynews.com/en/innovation-how-startup-habs,25871
Articles about Human Augmented Brain Systems (HABS)
- HABS's EEG Sensor Aims to Decode Stress Before It Becomes a Mistake — The French neurotech startup is targeting high-risk sectors with a non-invasive wearable that reads brainwaves for cognitive risk detection.